Phosphoramidate nucleoside derivatives as anticancer agents
US10906929B2 · kind B2 · utility
2Cited by
9References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 31, 2017 |
| Grant date | Feb 2, 2021 |
| Priority date | — |
| Expiry date | May 31, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07H19/173
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
This invention relates to derivatives of cladribine of Formula (I). The compounds are phosphoramidate derivatives in which the phosphoramidate moiety is situated on the 3′-hydroxyl group of cladribine. The invention also relates to pharmaceutical formulations of the cladribine derivatives and their use in methods of treatment. The compounds are useful in the treatment of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.